Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Down again this morning on the Swiss exchange. I find it interesting that the trend is lower on the verge of news but it's not a capitulation in anticipation of bad news. It's as though no news is expected and we're range bound.
GameStop Trading Could Be ‘Systemically Wrong,’ State Regulator Says
https://www.marketwatch.com/articles/gamestop-trading-could-be-systemically-wrong-massachusetts-state-regulator-says-51611705870?mod=home-page
I see Enron is mentioned in there too. Hmm
Their doctors should tell them to eat more. ;)
Two Indian generics, Reddys and another, are going to conduct phase 3 trials for covid with aviptadil.
The India trial news? A longer look at the Acer deal? Profit taking? Take your pick.
I can only see three reasons for the delay in releasing data. The data is not strong and they are massaging it to try and salvage a favorable outcome. The trial failed and they are withholding data. There are ongoing negotiations for a buyout.
I believe you have said you think they will achieve their primary endpoint. Please correct me if that's wrong. That leaves out a trial failure but leaves open the possibility that the results are muddied. As for a buyout, to quote a line from True Grit: I don’t believe fairy tales or sermons or stories about money
Acer does have a drug, edsivo, that still has potential but needs funding for further trials according to the FDA. They denied approval but pointed the way forward for potential approval. Acer doesn't have the money to continue the trial and that's potentially where relief might come in. Frankly, after reading about Acers problems I'm surprised they're still listed.
https://ehlersdanlosnews.com/2020/03/26/fda-denies-acers-appeal-for-edsivo-a-potential-vascular-eds-therapy/
Why are other companies running trials with relief's drug? Anyone?
Shouldn't there be a patent issue with this?
You mean reoccupied. ;)
No surprise. This represents a bailout for them. Given the recent delay of their primary drug they've been running on fumes.
Looks like a loan to Acer to fund development of their drug, acer 001, which should have results of their trial this quarter. Relief will share in the revenue from the drug should it gain approval. The 4 million dollar loan will be backed by all assets of Acer. Acer received bad news last year regarding its edsivo drug and looks like they're on the ropes as far as finances.
This abstract was also at that link.
Abstract
In recent years, VIP/PACAP/secretin family has special interest. Family members are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, glucagon like peptide-1 (GLP(1)), GLP(2), gastric inhibitory peptide (GIP), growth hormone releasing hormone (GHRH or GRF), and peptide histidine methionine (PHM). Most of the family members present both in central nervous system (CNS) and in various peripheral tissues. The family members that are released into blood from periphery, especially gut, circulate the brain and they can cross the blood brain barrier. On the other hand, some of the members of this family that present in the brain, can cross from brain to blood and reach the peripheral targets. VIP, secretin, GLP(1), and PACAP 27 are transported into the brain by transmembrane diffusion, a non-saturable mechanism. However, uptake of PACAP 38 into the brain is saturable mechanism. While there is no report for the passage of GIP, GLP(2), and PHM, there is only one report that shows, glucagon and GHRH can cross the BBB. The passage of VIP/PACAP/secretin family members opens up new horizon for understanding of CNS effects of peripherally administrated peptides. There is much hope that those peptides may prove to be useful in the treatment of serious neurological diseases such as Alzheimer's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS related neuropathy, diabetic neuropathy, autism, stroke and nerve injury. Their benefits in various pathophysiologic conditions undoubtly motivate the development of a novel drug design for future therapeutics.
Powerful Run on Relief Therapeutics Holding SA (SWX: RLF) (OTCQB: RLFTF) Phase 2b/3 Trial Top Line Data Coming & ZYESAMI™ (RLF-100TM: aviptadil) Trials
https://microcapdaily.com/powerful-run-on-relief-therapeutics-holding-sa-swx-rlf-otcqb-rlftf-phase-2b-3-trial-top-line-data-coming-zyesami-rlf-100tm-aviptadil-trials/129959/
Thanks. Didn't know that.
The stock is up over 11% on the Swiss exchange this morning on 30 million share volume. Looks like today will be a good one.
Just to piggyback on your post, a poster there,Vader, links to a Reddit post that claims the data will be unblinded tomorrow. Comments anyone?
Not really low volume. Half a million shares in half an hour. If there was news it would be a lot more but it's definitely not low volume. In fact, if the trend holds it will be above the ten day average.
What the heck! Marketwatch shows the price down 3 cents in after hours trading. Since this stock doesn't trade after hours it looks like mm's finished cleaning house after the bell. Anybody else see that?
Maybe not. It's back below $1.30. I don't think the market is pleased with the news even though it's months out of date. Dilution is never good without good news.
The news doesn't seem to have an effect on the stock price this morning except to maybe stop the bleeding.
I've never seen that as a reason to buy back shares. Given the way corporate leadership works these days I suspect it's to increase executive pay.
I read an article yesterday saying spac mergers will be less popular this year. I have no idea why as the article didn't elaborate .
Same with Schwab
I didn't clear it up in afraid. That scenario is just speculation on my part.
Schwab shows the low for the day .0786,so 8 cents for the low this morning. An old standing bid meets up with a market sell order in a slack moment?
It is always the case that budget authorizations originate in the House. The Senate can alter those authorizations in committee and the bill will go to reconciliation and after they pass it the president signs off on it. The presidents role in the process is to offer budget proposals which Congress may or may not accept.
How can they use a trademarked name to sell a fake drug?
Pardon my ignorance but I thought all revenue bills started in the House.
Up 19% on the Swiss exchange this morning
If NWBO expects a decent buyout price the stock needs to run because, as noted here previously, no one is going to offer a premium much above 50% of the then current stock price. To me, that means they will have to file their 10k or suffer the consequences.
The fat lady hasn't warmed up yet. I'll wait for topline data and see what happens . If the data is good and the FDA still doesn't act there's a possibility Europe will. So I'm hanging around.
The Swiss market has creeped back up a bit off their low. I think we will open down 40 to 50 percent and hopefully drift back up. Looking for an opening here at around 20 cents on very heavy volume.
Any idea why it was rejected? Prior art? Efficacy? The patent appeals board would be the last stop for them to get it approved and I don't think the odds there are good.
Biden has said he plans to reverse Trump's tax cuts. I take that to include capital gains taxes.
Bear raid incoming?
Quick. Check Mercks website and see if the format is the same! ;)
Don't forget the facility discussed here a while back that's being constructed in Memphis that reportedly had the capability to produce dcvax.
I don't believe dcvax qualifies under the eua program as that's reserved for national health emergencies where no approved medication is available.
Medicare part B covers Keytruda after deductible with a 20% copay. Still expensive for most folks. I would expect dcvax to get the same coverage eventually.
https://www.healthline.com/health/medicare/does-medicare-cover-keytruda